Amneal Pharmaceuticals, Inc.
corporate_fare Company Profile
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 40 items for AMRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for AMRX spans 10-Q, 8-K/A, SCHEDULE 13D/A, 8-K.
Recent high-impact activity:
- European Commission Approves Amneal's XOLAIR Biosimilar Adcomfo
- Amneal 10-Q: Q3 Revenue Up 10% to $863M, but Kashiv Deal Drives $21.7M Quarterly Loss
- Amneal Posts 6-Cent Loss Per Share in Third Quarter
- Amneal Lifts 2026 Guidance as Q3 Revenue Climbs 10% to $863M
- Amneal 8-K/A Reveals Kashiv Going-Concern Doubt and Restatement in Deal Financials
Financial Snapshot
Short Interest & Short Volume
2.79 days to coverFINRA reported short interest of 11,389,253 shares in AMRX as of the October 30, 2026 settlement, a 19.0% decrease from the prior period — about 2.8 days to cover at its recent average daily volume. On November 20, 2026, 74.1% of AMRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for AMRX, detected from its recent SEC filings.
28.9M Shares Registered for Resale · No Proceeds to Company
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →